MENLO PARK, CA
LevitasBio, biotech leader in label-free sample enrichment for cellular analysis, today announced the expansion of its leadership team with the appointment of two senior leaders from the biotech industry to lead commercial strategy and finance. Paul Steinberg, a veteran commercial and strategic leader in life sciences tools, has been appointed Chief Commercial Officer. Joseph Walthers has joined as VP of Finance, bringing deep financial and strategic operations expertise in the high growth life sciences space.
In his new role, Mr. Steinberg is responsible for leading LevitasBio’s commercial roadmap and strategy, accelerating adoption of its technology across key applications, and managing the commercial functions of the company. His leadership will help LevitasBio solidify its industry-leading position in next-generation sample preparation and characterization. Prior to joining LevitasBio, Mr. Steinberg has previously led worldwide commercialization and business development efforts for flagship biotechnology companies including Thermo Fisher Scientific, Fluidigm, and Nanostring.
“LevitasBio is poised to significantly enhance the outcome of cellular-based workflows and expand discoveries that could not otherwise be achieved from naturally complex sample types,” said Paul Steinberg, Chief Commercial Officer, LevitasBio. “LeviCell technology empowers a broad range of applications from single cell genomic characterization to iPSC-derived cell line enrichment, and serves the continuum of scientific pursuit from discovery to clinical use. I am excited to join LevitasBio in this critical part of its journey.”
In his new role, Mr. Walthers will be responsible for all financial planning, budgeting, accounting operations, risk management and internal controls activities. He will provide strategic guidance around capital financing options to support the company’s growth through commercialization. Mr. Walthers has over 20 years experience in Life Science and Biotech companies in financial leadership positions including Twist Bioscience, Natera and RAININ Instrument. He holds an active CPA license in the State of California.
“The technology will add great value to companies working on cellular level research,” said Joe Walthers, VP of Finance, LevitasBio. “I am thrilled to be part of the LevitasBio team supporting the company during this critical stage of commercial growth.”
Based on technology developed at Stanford University and Harvard University, LevitasBio has pioneered the use of magnetic-induced density gradients to enrich targeted cells from complex samples, without dyes or manipulation. Its first platform, the LeviCell, was launched in mid-2020 and allows researchers to remove debris and dead cells from samples in minutes with no dyes or labels and with minimal manual labor. The company has also recently completed an $18 million Series B financing round to support business expansion.
“Now that we have launched the LeviCell, demonstrated our technology’s impact in cellular analysis and sample enrichment, and closed our series B, the timing could not be more ideal for us to have a seasoned sales leader like Paul to take our technology to customers worldwide and the addition of Joe to set us on a path for sustainable growth” says Martin Pieprzyk, Chief Executive Officer at LevitasBio.
LevitasBio is a life science technology company developing products and solutions to enable analysis and understanding of biology, ultimately providing tools for a better tomorrow. The company’s Magnetic Levitation technology is based on inventions from Stanford University and Harvard University and for the first time enables a true, unbiased, and unaltered view of the biological world. Founded in 2017, LevitasBio’s product portfolio already includes over 20 commercial applications ranging from Oncology, Immunology to Bacteriology, all with unique and powerfully enabling value propositions not available in the market today.
Chief Commercial Officer